VIDEO: Trulance yields rapid, durable response in chronic idiopathic constipation
Click Here to Manage Email Alerts
LAS VEGAS — In this video exclusive, Eric Shah, MD, MBA, of Dartmouth-Hitchcock Health in Lebanon, New Hampshire, discussed the use of Trulance in patients with chronic idiopathic constipation.
The research was presented at the ACG Annual Scientific Meeting.
Shah and colleagues compared Trulance 3 mg (plecanatide, Salix Pharmaceuticals) with placebo with regard to time to first weekly response. In addition, they looked at the number of weeks that patients had a response during the trial, as well as abdominal pain and bloating response.
Shah said patients who took plecanatide compared with placebo had a shorter time to achieve a clinically meaningful response on bowel movement frequency endpoints. He noted this occurred rapidly, in about 3 weeks and was sustained for about 12 weeks.
“There was a more rapid response and a more durable response in taking plecanatide compared with placebo,” Shah said.
Collapse
Shah E, et al. Poster: P1448. Presented at: ACG Annual Scientific Meeting; Oct. 22-27, 2021; Las Vegas (hybrid meeting).
Read more about
Click Here to Manage Email Alerts